+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Severity of age-related macular degeneration in 1 eye and the incidence and progression of age-related macular degeneration in the fellow eye: the Beaver Dam Eye Study



Severity of age-related macular degeneration in 1 eye and the incidence and progression of age-related macular degeneration in the fellow eye: the Beaver Dam Eye Study



JAMA Ophthalmology 133(2): 125-132



Previous studies regarding the severity of age-related macular degeneration (AMD) in 1 eye and its prognostic implications for the fellow eye have focused on the incidence of neovascular AMD in the fellow eye of participants with neovascular AMD in the other eye. It is unclear to what extent the severity of AMD in 1 eye affects the incidence, progression, and regression of AMD in its fellow eye across the entire range of AMD severity. To investigate the effect of the severity of AMD in 1 eye on the incidence, progression, and regression of AMD in the fellow eye. The Beaver Dam Eye Study is a longitudinal population-based study of age-related eye diseases conducted in the city and township of Beaver Dam, Wisconsin. Examinations were performed every 5 years over a 20-year period (from the baseline examination in 1988-1990 to 2008-2010). Study participants (n = 4379) were 43 to 86 years of age at the baseline examination. At baseline and in up to 4 subsequent examinations, retinal photographs were taken. Incidence, progression, and regression of AMD (assessed by use of the Wisconsin Age-Related Maculopathy Grading System on retinal photographs and adjusted for age, sex, and the Y402H polymorphism in the complement factor H gene on chromosome 1q) and mortality. More severe AMD in 1 eye was associated with increased incidence of AMD and accelerated progression in its fellow eye (levels 1-2: hazard ratio [HR], 4.90 [95% CI, 4.26-5.63]; levels 2-3: HR, 2.09 [95% CI, 1.42-3.06]; levels 3-4: HR, 2.38 [95% CI, 1.74-3.25]; levels 4-5: HR, 2.46 [95% CI, 1.65-3.66]). Less severe AMD in 1 eye was associated with less progression of AMD in its fellow eye (levels 2-3: HR, 0.42 [95% CI, 0.33-0.55]; levels 3-4: HR, 0.50 [95% CI, 0.34-0.83]). We estimate that 51% of participants who develop any AMD always maintain AMD severity states within 1 step of each other between eyes; 90% of participants stay within 2 steps. Using multistate models, we show that AMD severity in 1 eye tracks AMD severity in its fellow eye.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055741960

Download citation: RISBibTeXText

PMID: 25340497

DOI: 10.1001/jamaophthalmol.2014.4252


Related references

Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 123(7): 1530-1540, 2016

Development of typical age-related macular degeneration and polypoidal choroidal vasculopathy in fellow eyes of Japanese patients with exudative age-related macular degeneration. American Journal of Ophthalmology 146(1): 96, 2008

Night vision symptoms and progression of age-related macular degeneration in the Complications of Age-related Macular Degeneration Prevention Trial. Ophthalmology 115(11): 1876-1882, 2008

Further observations on the association between smoking and the long-term incidence and progression of age-related macular degeneration: the Beaver Dam Eye Study. Archives of Ophthalmology 126(1): 115-121, 2008

Statin Use and the Incidence of Advanced Age-related Macular Degeneration in the Complications of Age-related Macular Degeneration Prevention Trial. Yearbook of Ophthalmology 2010: 127-129, 2010

Statin use and the incidence of advanced age-related macular degeneration in the Complications of Age-related Macular Degeneration Prevention Trial. Ophthalmology 116(12): 2381-2385, 2009

Effect of the Y402H variant in the complement factor H gene on the incidence and progression of age-related macular degeneration: results from multistate models applied to the Beaver Dam Eye Study. Archives of Ophthalmology 130(9): 1169-1176, 2012

Assessment of retinal vessel caliber changes in eyes with non-neovascular age-related macular degeneration after progression to neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 254(3): 599-601, 2016

Incidence and risk factors for neovascular age-related macular degeneration in the fellow eye. Graefe's Archive for Clinical and Experimental Ophthalmology 256(11): 2061-2068, 2018

Macular function in eyes with early age-related macular degeneration with or without contralateral late age-related macular degeneration. Retina 27(7): 879-890, 2007

Rapid progression of subclinical age-related macular degeneration in the untreated fellow eye after intravitreal bevacizumab. Acta Ophthalmologica 87(6): 685-687, 2009

The Contribution of Genetic Architecture to the 10-Year Incidence of Age-Related Macular Degeneration in the Fellow Eye. Investigative Ophthalmology and Visual Science 56(9): 5353-5361, 2015

Incidence of Fellow Eye Involvement in Patients With Unilateral Exudative Age-Related Macular Degeneration. JAMA Ophthalmology 136(8): 905-911, 2018

Drusen Volume as a Predictor of Disease Progression in Patients With Late Age-Related Macular Degeneration in the Fellow Eye. Investigative Ophthalmology and Visual Science 57(4): 1839-1846, 2016

Risk Factors and Age-Related Macular Degeneration in a Mediterranean-Basin Population: The PAMDI (Prevalence of Age-Related Macular Degeneration in Italy) Study--Report 2. Ophthalmic Research 55(3): 111-118, 2016